Neural mechanisms and management of obesity-related hypertension

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 456-463

  Esler, Murray D ^a   Eikelis, Nina ^b   Lambert, Elisabeth ^b   Straznicky, Nora ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LEPTIN; MOXONIDINE; NORADRENALIN; RILMENIDINE;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; AEROBIC EXERCISE; ARTICLE; BODY WEIGHT; CALORIC RESTRICTION; CARDIOPULMONARY HEMODYNAMICS; CENTRAL NERVOUS SYSTEM FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EATING HABIT; ENERGY BALANCE; ENERGY EXPENDITURE; ESSENTIAL HYPERTENSION; HEART INNERVATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART STROKE VOLUME; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS; INSULIN RESISTANCE; KIDNEY INNERVATION; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; MUSCLE BLOOD FLOW; MUSCLE CONTRACTION; MUSCLE INNERVATION; NERVE FIBER; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; SUDDEN DEATH; SYMPATHETIC BLOCKING; SYMPATHETIC INNERVATION; SYMPATHETIC TONE; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION;

HUMANS; HYPERINSULINISM; HYPERTENSION; LEPTIN; OBESITY; RECEPTORS, ADRENERGIC, BETA-3; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM; WEIGHT LOSS;

EID: 58249092194     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0072-7     Document Type: Article

References (50)

1. Landsberg L, Young JB: Fasting, feeding and regulation of the sympathetic nervous system. N Engl J Med 1978, 298:1295-1301.
2. Jung RT, Shetty PS, James WPT: The effect of beta-adrenergic blockade on resting metabolic rate and peripheral thyroid metabolism in obesity. Eur J Clin Invest 1980, 10:179-182.
3. Bielinski R, Schutz Y, Jequier E: Energy metabolism during postexercise recovery in man. Am J Clin Nutr 1985, 42:69-82.
4. Schwartz RS, Jaeger LF, Veith RC: Effect of clonidine on the thermic effect of feeding in humans. Am J Physiol 1988, 254:R90-R94.
5. Bray GA, York DAA Fisler JS: Experimental obesity: a homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system. Vitam Horm 1989, 45:1-125.
6. Young JB, MacDonald IA: Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 1992, 16:959-967.
7. Rocchini AP, Moorhead C, DeRemer S, Bondie D: Pathogenesis of weight-related changes in blood pressure in dogs. Hypertension 1989, 13:922-928.
8. Kassab S, Kato T, Wilkins FC, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893-897.
9. Antic V, Dulloo A, Montani JP: Short-term (5-day) changes in food intake alter daily hemodynamics in rabbits. Am J Hypertens 2003, 16:302-306.
10. Landsberg L: Diet, obesityAand hypertension: a hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986, 236:1081-1090.
11. von Euler US: A specific sympathetic ergone in adrenergic nerve fibres (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946, 12:73-97.
12. Esler M, Jennings G, Lambert G, et al.: Overflow of catecholamine neurotransmitters to the circulation: Source, fate and functions. Physiol Rev 1990, 70:963-985.
13. Grassi G, Colombo M, Seravalle G, et al.: Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998, 31:64-67.
14. Macefield V, Wallin BG, Vallbo AB: The discharge behaviour of single vasoconstrictor motor neurones in human muscle nerves. J Physiol 1994, 481:799-809.
15. Esler M, Jennings G, Korner P, et al.: The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988, 11:3-20.
16. Rumantir MS, Vaz M, Jennings GL, et al.: Neural mechanisms in human obesity-related hypertension. J Hypertens 1999, 17:1125-1133.
17. Esler M: Looking at the sympathetic nervous system as a primary source. In Handbook of Hypertension: Hypertension Research in the Twentieth Century. Edited by Zanchetti A, Robertson JIS, Bikenhager WH. Amsterdam: Elsevier; 2004:81-103.
18. Greenwood JP, Stoker JB, Mary DASG: Single-unit sympathetic discharge. Quantitative assessment in human hypertensive disease. Circulation 1999, 100:1305-1310.
19. Lambert E, Straznicky N, Schlaich M, et al.: Differing patterns of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007, 50:862-868.
20. DiBona GF: Sympathetic neural control of the kidney in hypertension. Hypertension 1992, 19:I28-I35.
21. Messerli FH, Sundgaard-Riise K, Reisin E, et al.: Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983, 74:808-812.
22. Sjostrom L: Morbidity and mortality of severely obese subjects. Am J Clin Nutr 1992, 55:508S-515S.
23. Hall JE, Brands MW, Hildebrandt DA, Mizelle HL: Obesity-associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension 1992, 19:I45-I55.
24. Julius S, Valentini M, Palatini P: Overweight and hypertension. A 2-way street? Hypertension 2000, 36:807-813.
25. Masuo K, Kawaguchi H, Mikami H: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42:474-480.
26. Ferrier C, Jennings GL, Eisenhofer G, et al.: Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. J Hypertens 1993, 11:1217-1227.
27. Esler M, Eikelis N, Schlaich M, et al.: Chronic mental stress is a cause of essential hypertension: Presence of biological markers of stress. Clin Exp Pharm Physiol 2008, 35:498-502.
28. Esler M, Lambert G, Vaz M, et al.: Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens 1997, 19:577-590.
29. Haynes WG, Sivitz WI, Morgan DA, et al.: Sympathetic and cardiorenal actions of leptin. Hypertension 1997, 30:619-623.
30. Narkiewicz K, Van de Borne PJH, Cooley RL, et al.: Sympathetic activity in obese subjects with and without obstructive sleep apnoea. Circulation 1998, 98:772-776.
31. Grassi G, Facchini A, Trevano FQ, et al.: Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005, 46:321-325.
32. Masuo K, Katsuya T, Fu Y, et al.: Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005, 111:3429-3434.
33. Green SA, Cole G, Jacinto M, et al.: A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993, 268:23116-23121.
34. Schlaich MP, Kaye DM, Lambert E, et al.: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003, 108:560-565.
35. Julius S, Gundrandsson T, Jamerson K, et al.: The interconnection between sympathetics, microcirculation and insulin resistance in hypertension. Blood Press 1992, 1:9-19.
36. Esler M, Straznicky N, Eikelis N, et al.: Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006, 48:787-796.
37. Haenni A, Lithell H: Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999, 19:S29-S35.
38. Bell-Anderson KS, Bryson JM: Leptin as a potential treatment for obesity: Progress to date. Treat Endocrinol 2004, 3:11-18.
39. O'Dea K, Esler M, Leonard P, et al.: Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism 1982, 31:896-899.
40. Laaksonen DE, Laitinen T, Schonberg J, et al.: Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome. J Hypertens 2003, 21: 371-378.
41. Esler M: On a low calorie diet, are there separate and discrete effects of negative energy balance and weight loss on blood pressure? J Hypertens 2003, 21:261-262.
42. Dickinson HO, Mason JM, Nicolson DJ, et al.: Lifestyle interventions to reduce raised blood pressure: A systematic review of randomized controlled trials. J Hypertens 2006, 24:215-233.
43. Meredith IT, Friberg P, Jennings GL, et al.: Regular exercise lowers renal but not cardiac sympathetic activity in man. Hypertension 1991, 18:575-582.
44. Hasking G, Esler M, Jennings G, et al.: Norepinephrine spillover to plasma in congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986, 73:615-621.
45. Kaye DM, Lefkovits J, Jennings GL, et al.: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26:1257-1263.
46. Packer M, Bristow MR, Cohn JN, et al.: The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
47. Sharma AM, Wagner T, Marsalek P: Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: A postmarketing surveillance study. J Hum Hypertens 2004, 18:669-675.
48. Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2002, 14:694-698.
49. Grassi G, Servalle G, Dell'Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
50. Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. Hypertension 1997, 30:140-145.